AstraZeneca’s Alexion posts 52-week PREVAIL data backing once-weekly self-injected C5 inhibitor gefurulimab in gMG

• AstraZeneca flagged new long-term trial results for gefurulimab in generalized myasthenia gravis, scheduled for presentation in late September 2026.
• Data from the PREVAIL Phase 3 open-label extension indicated sustained symptom control through 52 weeks in treated adults.
• Patients switching from placebo showed rapid improvement soon after starting therapy, with benefits maintained to one year.
• Safety profile remained consistent, with no meningococcal infections reported, supporting positioning as a self-administered weekly injection.
• Separate analyses due at the same meetings pointed to fewer hospitalizations and less rescue therapy use versus placebo earlier in the study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on September 24, 2026, and is solely responsible for the information contained therein.